1-[(2-methylbut-3-yn-2-yl)oxy]-4-(trifluoromethyl)benzene | 120281-22-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(2-methylbut-3-yn-2-yl)oxy]-4-(trifluoromethyl)benzene
• 英文别名: 4-(1,1-Dimethyl-2-propynyloxy)trifluoromethylbenzene；1-(2-methylbut-3-yn-2-yloxy)-4-(trifluoromethyl)benzene
• CAS: 120281-22-3
• 化学式: C₁₂H₁₁F₃O
• 分子量: 228.214
• InChiKey: NJFZPSSHFSLBED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[(2-methylbut-3-yn-2-yl)oxy]-4-(trifluoromethyl)benzene 在 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 水 作用下， 以 乙醚 、 二甲基亚砜 、 邻二氯苯 为溶剂， 反应 1.0h， 生成 3,4-dihydro-2,2-dimethyl-3,4-epoxy-6-(trifluoromethyl)-2H-1-benzopyran
  参考文献：
  名称：

  Variation in the aromatic ring of cromakalim: antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans

  摘要：

  The synthesis and antihypertensive activity in the spontaneously hypertensive rat of two new series of analogues related to cromakalim (1) are described. In the first series, where the benzopyran nucleus has been replaced by a pyranopyridine nucleus, the position of the nitrogen atom has been found to be critical for activity, and the most potent compounds are the pyrano[3,2-c]pyridines. In the second series, where the powerful electron-withdrawing cyano group of compound 1 has been replaced by alkyl and phenyl groups, the order of antihypertensive potency is ethyl, isopropyl, tert-butyl greater than propyl, cyclopentyl greater than methyl greater than phenyl.

  DOI：

  10.1021/jm00173a018
• 作为产物：
  描述：

  4-三氟甲基苯硼酸 在 三氟化硼乙醚 、 sodium hexamethyldisilazane 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 正戊烷 为溶剂， 反应 4.67h， 生成 1-[(2-methylbut-3-yn-2-yl)oxy]-4-(trifluoromethyl)benzene
  参考文献：
  名称：

  立体拥挤的烷基芳基醚的轻度合成

  摘要：

  提出了一种通过叔醇与邻位取代的二芳基碘鎓盐的芳基化反应来获得叔烷基芳基醚的有效且无过渡金属的方法。范围包括环状和无环脂族，苄基，烯丙基和炔丙基叔醇，以及伯和仲氟化醇。该方法使人们可以获得以前前所未有的空间拥塞的烷基芳基醚。此外，通过药物前体雌二醇的芳基化证明了所开发方法的多功能性。

  DOI：

  10.1021/acs.orglett.6b01975

文献信息

• Benzopyran derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04971982A1

  公开（公告）日：1990-11-20

  Compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, halogen, trifluoromethyl, nitro, cyano, lower alkyl, lower alkoxycarbonyl, lower alkylthio, lower alkylsulphonyl, lower alkanoyl, aroyl, carbamoyl, mono(lower alkyl)carbamoyl or di(lower alkyl)carbamoyl, R.sup.2 is hydrogen, lower alkyl or phenyl, R.sup.3 is hydrogen or lower alkyl, R.sup.4 and R.sup.5 each is hydrogen or R.sup.4 is hydroxy and R.sup.5 is hydrogen or R.sup.4 and R.sup.5 together are a carbon-carbon bond and R.sup.6 is an aryl or N-heteroaryl group carrying a hydroxy group in the 2-position or, in the case of a N-heteroaryl group, also a N-oxide group in the 2-position, and pharmaceutically acceptable acid addition salts of these compounds of formula I which are basic, possess pronounced potassium channel activating activity and can be used as medicaments, particularly in the control or prevention of hypertension, congestive heart failure, angina pectoris, peripheral and cerebral vascular disease and smooth muscle disorders.

  公式的化合物##STR1##，其中R.sup.1是氢、卤素、三氟甲基、硝基、腈、低级烷基、低级烷氧基羰基、低级烷基硫醚、低级烷基亚磺酰基、低级烷氧基、芳酰基、氨基甲酰基、单（低级烷基）氨基甲酰基或二（低级烷基）氨基甲酰基，R.sup.2是氢、低级烷基或苯基，R.sup.3是氢或低级烷基，R.sup.4和R.sup.5各自是氢或R.sup.4是羟基且R.sup.5是氢或R.sup.4和R.sup.5一起是碳-碳键，R.sup.6是一个在2-位带有羟基的芳香族或N-杂芳族基团，或者在N-杂芳族基团的情况下，还在2-位带有N-氧化物基团，以及这些公式I的化合物的药用可接受的酸加成盐，它们是碱性的，具有显著地激活钾通道的活性，可以用作药物，特别是在控制或预防高血压、充血性心力衰竭、心绞痛、外周和脑血管疾病以及平滑肌障碍中。
• [EN] CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS<br/>[FR] CHROMÈNE ET 1,1A,2,7B-TÉTRAHYDROCYCLOPROPA[C]CHROMÈNE PYRIDOPYRAZINEDIONES COMME MODULATEURS DE GAMMA-SÉCRÉTASE
  申请人：PFIZER

  公开号：WO2015150957A1

  公开（公告）日：2015-10-08

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. These compounds are γ-secretase modulators, useful for the treatment of neurodegenerative and/ or neurological disorders such as Alzheimer's disease and Down's syndrome.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有式（I）的结构，其中X、R1、R2a、R2b、R4a、R4b、R5a、R5b、R6、R7、y和z如规范中所定义。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。这些化合物是γ-分泌酶调节剂，可用于治疗神经退行性和/或神经系统疾病，如阿尔茨海默病和唐氏综合征。
• [EN] ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] COMPOSÉS ÉTHER D'ARYLE ET ÉTHER D'HÉTÉROARYLE EN TANT QUE MODULATEURS DE ROR GAMMA
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2015159233A1

  公开（公告）日：2015-10-22

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

  本公开涉及式(I)的化合物及其药用盐，其中环A、环B、R、R2、R3、n和p如本文所定义，这些化合物作为视黄酸相关孤儿受体γt（RORγt）的调节剂具有活性。这些化合物可以预防、抑制或抑制RORγt的作用，因此在治疗RORγt介导的疾病、疾病、综合症或症状方面具有用处，例如疼痛、炎症、慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、结肠炎、多发性硬化、牛皮癣、神经退行性疾病和癌症。
• Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy
  作者：Martin Pettersson、Douglas S. Johnson、Danica A. Rankic、Gregory W. Kauffman、Christopher W. am Ende、Todd W. Butler、Brian Boscoe、Edelweiss Evrard、Christopher J. Helal、John M. Humphrey、Antonia F. Stepan、Cory M. Stiff、Eddie Yang、Longfei Xie、Kelly R. Bales、Eva Hajos-Korcsok、Stephen Jenkinson、Betty Pettersen、Leslie R. Pustilnik、David S. Ramirez、Stefanus J. Steyn、Kathleen M. Wood、Patrick R. Verhoest

  DOI：10.1039/c6md00406g

  日期：——

  γ-Secretase modulators for the treatment of Alzheimer's disease.

  γ-分泌酶调节剂用于治疗阿尔茨海默病。
• NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES
  申请人：Pfizer Inc.

  公开号：US20150274721A1

  公开（公告）日：2015-10-01

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R 1 , R 2a , R 2b , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药学上可接受的盐，其中该化合物具有I式结构，其中X、R1、R2a、R2b、R4a、R4b、R5a、R5b、R6、R7、y和z的定义在说明书中。同时还揭示了相应的药物组合物、治疗方法、合成方法和中间体。